New Injectable Treatment Helps Flat-Faced Dog Breeds Breathe Better

Brachycephalic breeds, such as Pugs and French Bulldogs, are beloved for their flat faces, but this physical trait often causes Brachycephalic Obstructive Airway Syndrome (BOAS).

Many of these dogs struggle to breathe, often requiring expensive and invasive surgery to clear their airways.

Recently, researchers from RMIT University and the biotech firm Snoretox have developed a promising new treatment called Snoretox-1.

This injectable therapy uses a modified tetanus toxin to increase muscle tone in the geniohyoid muscles at the base of the mouth, helping to stabilize the airway during inhalation.

Unlike traditional surgeries, this treatment does not require general anesthesia, making it a potentially safer and more accessible option.

In a recent clinical trial involving British Bulldogs, the therapy showed immediate success; dogs that previously struggled to walk for three minutes were able to complete brisk exercise with significantly reduced respiratory effort.

While the treatment is still in its early stages of development, it recently earned an Innovation Award, signaling a hopeful future for flat-faced dogs.

Researchers believe that if further testing confirms its safety and efficacy, this technology could eventually have wider applications in both veterinary and human medicine.